Abstract
Diabetes mellitus without previous myocardial infarction carries the same risk of a future myocardial infarction as someone who has had one. Intense glucose, lipid, and blood pressure control in diabeti patients is advocated to reduce cardiovascular events and decrease the incidence of end-stage renal disease, retinal damage, and peripheral vascular disease. Recent studies, including the Systolic Hypertension in the Elderly Program, indicate that low-dose diuretics, compared with placebo, reduce fatal and nonfatal myocardial infarctions but not fatal and nonfatal stroke in diabetic patients. Similarly, captopril (and diuretics) compared with diuretics and βblockers decreased fatal and nonfatal myocardial infarctions but not fatal and nonfatal strokes in the Captopril Prevention Project. Intense blood pressure therapy with captopril and intense blood pressure therapy with atenolol equally lowered macrovascular and microvascular events compared with less intense blood pressure treatment in the United Kingdom Prospective Diabetes Study. Fewer myocardial infarctions were seen with enalapril than with nisoldipine in the Appropriate Blood Pressure Control in Diabetes trial. Intense blood pressure control with felodipine, enalapril, and hydrochlorothiazide reduced overall cardiovascular events and mortality but not myocardial infarction and strokes in the Hypertension Optimal Treatment trial. Nitrendipine alone or together with enalapril and hydrochlorothiazide decreased fatal and nonfatal strokes and cardiovascular mortality but not myocardial infarctions in the Systolic Hypertension in Europe trial These trials, in aggregate, reinforce the importance of intense blood pressure control, which can be achieved only with combination drug therapy rather than a specific monotherapy drug class recommendation.
Similar content being viewed by others
References and Recommended Reading
Turner RC, Millns H, Neil HA, et al.: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998, 316:823–828.
American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care 1999, 22 S32-S41.
American Diabetes Association: Management of dyslipidemia in adults with diabetes. Diabetes Care 1999, 22:S56-S59.
The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997, 157:2413–2446.
Haffner SM, Lehto S, Ronnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229–234. Diabetes mellitus carries the same risk as a previous myocardial infarction
Pahor M, Kritchevsky SB, Zuccala G, Guralnik JM: Diabetes and risk of adverse events with calcium antagonists. Diabetes Care 1998, 21:193–194.
Berne C, Pollare T, Lithell H: Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care 1991, 14(suppl 4):39–47.
Swislocki AL, Hoffman BB, Reaven GM: Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens 1989, 2 (6 pt 1):419–423.
Prisant LM, Carr AA: Antihypertensive drug therapy and insulin resistance. Am J Hypertens 1992, 5:775–777.
Warram JH, Laffel LM, Valsania P, et al.: Excess mortality associated with diuretic therapy in diabetes mellitus. Arch Intern Med 1991, 151:1350–1356.
Neutel JM: Metabolic manifestations of low-dose diuretics. Am J Med 1996, 101:71S-82S.
Curb JD, Pressel SL, Cutler JA, et al.: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996, 276:1886–1892. Compared with placebo, low-dose diuretics reduced fatal and nonfatal myocardial infarctions but not fatal and nonfatal strokes.
Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611–616. Captopril (and diuretics) compared with diuretics and b-blockers decreased fatal and nonfatal myocardial infarctions but not fatal and nonfatal strokes.
United Kingdom Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998, 317:713–720.
United Kingdom Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703–713.
Borhani NO, Mercuri M, Borhani PA, et al.: Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 1996, 276:785–791.
Byington RP, Craven TE, Furberg CD, Pahor M: Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet 1997, 350:1075–1076.
Estacio RO, Jeffers BW, Hiatt WR, et al.: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998, 338:645–652. Fewer myocardial infarctions were seen with enalapril than with nisoldipine.
Estacio RO, Schrier RW: Antihypertensive therapy in type 2 diabetes: implications of the Appropriate Blood Pressure Control in Diabetes (ABCD) trial. Am J Cardiol 1998, 82:9R-14R.
Tatti P, Pahor M, Byington RP, et al.: Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998, 21:597–603.
Califf RM, Granger CB: Hypertension and diabetes and the Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET). More ammunition against surrogate end points. Diabetes Care 1998, 21:655–657.
Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351:1755–1762. Intense blood pressure control with felodipine, enalapril, and hydrochlorothiazide reduced overall cardiovascular events and mortality but not myocardial infarction and strokes.
Staessen JA, Thijs L, Gasowski J, et al.: Treatment of isolated systolic hypertension in the elderly: further evidence from the systolic hypertension in Europe (Syst-Eur) trial. Am J Cardiol 1998, 82:20R-22R.
Tuomilehto J, Rastenyte D, Birkenhager WH, et al.: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999, 340:677–684. Nitrendipine alone or in combination with enalapril and hydrochlorothiazide decreased fatal and nonfatal strokes and cardiovascular mortality but not myocardial infarctions.
Pahor M, Psaty BM, Furberg CD: Treatment of hypertensive patients with diabetes. Lancet 1998, 351:689–690.
Cutler JA: Calcium-channel blockers for hypertension—uncertainty continues. N Engl J Med 1998, 338:679–681.
Poulter NR: Calcium antagonists and the diabetic patient: a response to recent controversies. Am J Cardiol 1998, 82:40R-41R.
Parving HH: Calcium antagonists and cardiovascular risk in diabetes. Am J Cardiol 1998, 82:42R-44R.
Staessen JA, Fagard R, Thijs L, et al.: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997, 350:757–764.
Schrier RW, Estacio RO, Jeffers BW, et al. ABCD-2V: Appropriate Blood pressure Control in Diabetes-part 2 with Valsartan. Am J Hypertens1999, 12(part2):141A.
Davis BR, Cutler JA, Gordon DJ, et al.: Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens 1996, 9(4 pt 1):342–360. This trial has the potential to show whether one drug is superior to another in the treatment of diabetic hypertensive patients.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Prisant, L.M., Louard, R.J. Controversies surrounding the treatment of the hypertensive patient with diabetes. Curr Hypertens Rep 1, 512–520 (1999). https://doi.org/10.1007/s11906-996-0024-9
Issue Date:
DOI: https://doi.org/10.1007/s11906-996-0024-9